Evidence Synthesis for Decision Making in Healthcare

Evidence Synthesis for Decision Making in Healthcare

Volumn , Issue , 2012, Pages 1-282

  Welton, Nicky J ^a   Sutton, Alexander J ^b   Cooper, Nicola J ^b   Abrams, Keith R ^b   Ades, A E ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879414160     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119942986     Document Type: Book

References (269)

1. Claxton K., Posnett J. An economic approach to clinical trial design and research priority-setting. Health Economics 1996;5:513-524.
2. Stinnett A., Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analyses. Medical Decision Making 1998;18: S68-S80.
3. Laupacis A., Feeny D., Detsky A.S., Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaulations. Canadian Medical Association Journal 1992;146:473-481.
4. Coast J. Is economic evaluation in touch with society's health values ? British Medical Journal 2004;329: 1236.
5. Dolan P., Cookson R. A qualitative study of the extent to which health gain matters when choosing between groups of patients. Health Policy 2000;51:19-30.
6. Ades A.E., Claxton K., Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Economics 2005;14:373-381.
7. Doubilet P., Begg C.B., Weinstein M.C., Braun P., McNeill B.J. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Medical Decision Making 1985;5:157-177.
8. Critchfield G.C., Willard K.E. Probabilistic analysis of decision trees using Monte Carlo simulation. Medical Decision Making 1986;6:85-92.
9. Mulrow C.D. Rationale for systematic reviews. In: Chalmer I., Altman D.G., eds. Systematic Reviews. London: BMJ Publishing Group, 1995;1-8.
10. McAlister F., Laupacis A., Wells G.A., Sackett D.L. Users' guides to the medical literature. XIX Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. Journal of the American Medical Association 1999;282:1371-1377.
11. Turner R.M., Spiegelhalter D.J., Smith G.C.S., Thompson S.G. Bias modelling in evidence synthesis. Journal of the Royal Statistical Society, Series A 2009;172:21-47.
12. Felli J.C., Hazen G. A Bayesian approach to sensitivity analysis. Health Economics 1999;8:263-268.
13. Briggs A.H. A Bayesian approach to stochastic cost-effectiveness analysis. Health Economics 1999;8:257-261.
14. Lunn D.J., Thomas A., Best N., Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000;10:325-337.
15. National Institute for health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE, 2008.
16. Hunink M., Glasziou P., Siegel J., et al. Decision Making in Health and Medicine:Integrating Evidence and Values. Cambridge: Cambridge University Press, 2001.
17. Briggs A., Sculpher M., Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
18. Spiegelhalter D.J., Abrams K.R., Myles J. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York: John Wiley & Sons, Ltd, 2004.
19. Berry D.A. Statistics: A Bayesian Perspective. London: Duxbury, 1996.
20. O'Hagan A., Luce B. A Primer on Bayesian Statistics in Health Economics and Outcome Research. www.bayesian-initiative.com: Bayesian Initiative in Health Economics and Outcomes Research, MedTap Intl, 2003.
21. Lee P.M. Bayesian Statistics: An Introduction. London: Arnold, 1997.
22. Drummond M.F., Richardson W.S., O'Brien B.J., Levine M., Heyland D. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. Journal of the American Medical Association 1997;277:1552-1557.
23. Guyatt G.H., Sinclair J., Cook D.J., Glasziou P. Users' guides to the medical literature. XVI. How to use a treatment recommendation. Journal of the American Medical Association 1999;281:1836-1843.
24. Guyatt G.H., Sackett D.L., Cook D.J. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. Journal of the American Medical Association 1993;270:2598-2601.
25. Guyatt G.H., Haynes R.B., Jaeschke R.Z., et al. Users' guides to the medical literature:XXV. Evidence-based medicine: principles for applying the users' guides to patient care. Journal of the American Medical Association 2000;284:1290-1296.
26. Oxman A.D., Cook D.J., Guyatt G.H. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. Journal of the American Medical Association 1994;272:1367-1371.
27. Oxman A.D., SACKETT D.L., Guyatt G.H. Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group. Journal of the American Medical Association 1993;270:2093-2095.
28. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Chichester: The Cochrane Collaboration, John Wiley & Sons, Ltd, 2008.
29. Cooper N.J., Sutton A.J., Abrams K.R., Turner D., Wailoo A. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Economics 2003;13:203-226.
30. Spiegelhalter D.J., Abrams K.R., Myles J. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York: John Wiley & Sons, Ltd, 2004.
31. Lunn D.J., Thomas A., Best N., Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000; 10:325-337.
32. Higgins J.P.T., Spiegelhalter D.J. Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction. International Journal of Epidemiology 2002;31:96-104.
33. Silverman B.W. Density Estimation. London: Chapman and Hall, 1986.
34. Gelman A., Carlin J.B., Stern H.S., Rubin D.B. Bayesian Data Analysis. London: Chapman & Hall, 2004.
35. Ades A.E., Lu G., Higgins J.P.T. The interpretation of random effects meta-analysis in decision models. Medical Decision Making 2005;25:646-654.
36. Carlin J.B. Meta-analysis for 2 × 2 tables: a Bayesian approach. Statistics in Medicine 1992;11:141-158.
37. Spiegelhalter D.J. Bayesian graphical modelling: a case-study in monitoring health outcomes. Journal of the Royal Statistical Society, Series C 1998;47:115-133.
38. Cowles M.K., Carlin B.P. Markov Chain Monte Carlo convergence diagnostics: a comparative review. Journal of the American Statistical Association 1996;91:883-904.
39. Brooks S.P., Gelman A. Alternative methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998;7:434-455.
40. Gelman A., Rubin D.B. Inferences from iterative simulation using multiple sequences. Statistical Science 1992;7:457-472.
41. National Institute of Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdated June2008.pdf.
42. Food and Drug Administration. Challenge and Opportunity on the Critical Path to New Medical Products. 2004. http://www.fda.gov/downloads/ScienceResearch/ SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf.
43. Berry D.A. Statistics: A Bayesian Perspective. London: Duxbury, 1996.
44. Gilks W.R., Richardson S., Spiegelhalter D.J. Markov Chain Monte Carlo in Practice. London: Chapman & Hall/CRC, 1996.
45. Lee P.M. Bayesian Statistics: An Introduction. London: Arnold, 1997.
46. O'Hagan A., Luce B. A Primer on Bayesian Statistics in Health Economics and Outcome Research. www.bayesian-initiative.com. Bayesian Initiative in Health Economics and Outcomes Research, MedTap Intl, 2003.
47. Congdon P. Bayesian Statistical Modelling. Chichester: John Wiley & Sons, Ltd, 2001.
48. Congdon P. Applied Bayesian Modelling. Chichester: John Wiley & Sons, Ltd, 2003.
49. Bower P., Byford S., Barber J., et al. Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses. British Medical Journal 2003;326:1247-1250.
50. Briggs A., Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13(4):397-409.
51. Hunink M., Glasziou P., Siegel J., et al. Constrained resources. In: Decision Making in Health and Medicine. Cambridge: Cambridge University Press, 2001;245-304.
52. Brennan A., Akehurst R. Modelling in health economic evaluation: What is its place? What is its value? Pharmacoeconomics 2000;17(5):445-459.
53. Buxton M.J., Drummond M.F., Van Hout B.A., et al., Modelling in economic evaluation:An unavoidable fact of life. Health Economics 1997;6:217-227.
54. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17(5):479-500.
55. Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan F.A., ed. Valuing Health Care. Cambridge: Cambridge University Press, 1996;185-205.
56. Pocock S.J. Clinical Trials: A Practical Approach. Chichester: John Wiley & Sons, Ltd, 1983.
57. Senn S. Cross-over Trials in Clinical Research. Chichester: John Wiley & Sons, Ltd, 1993.
58. Donner A., Klar N. Design and Analysis of Cluster Randomization Trials in Health Research. London: Arnold, 2000.
59. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated February 2008]. Chichester: The Cochrane Collaboration, John Wiley & Sons, Ltd, 2008.
60. Altman D.G., Deeks J.J. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Medical Research Methodology 2002;2 (available at: http://www. biomedcentral.com/1471-2288/2/3).
61. Fleiss J.L. The statistical basis of meta-analysis. Statistical Methods in Medical Research 1993;2:121-145.
62. Sutton A.J., Abrams K.R., Jones D.R., et al. Methods for Meta-Analysis in Medical Research. Chichester: John Wiley & Sons, Ltd, 2000.
63. Deeks J.J., Altman D.G. Effect measures for meta-analysis of trials with binary outcomes. In: Egger M., Davey Smith G., Altman D.G., eds. Systematic Reviews in Health Care. Meta-Analysis in Context. London: BMJ Publishing Group, 2001.
64. Sweeting M.J., Sutton A.J., Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23:1351-1375.
65. Hedges L.V., Olkin I. Statistical Methods for Meta-Analysis. London: Academic Press, 1985.
66. Welton N.J., Cooper N.J., Ades A.E., et al. Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B. Statistics in Medicine 2008;27:5620-5639.
67. Glick H.A., Doshi J.A., Sonnad S.A., et al., Economic evaluation in clinical trials. In:Gray A., Briggs A., eds. Handbooks in Health Economic Evaluation. Oxford: Oxford University Press, 2007.
68. Wikipedia. Central Limit Theorem (cited December 2008).
69. Whitehead A. Meta-Analysis of Controlled Clinical Trials, 1st edn. Chichester: John Wiley & Sons Ltd, 2002.
70. Cooper N.J., Sutton A.J., Lu G., et al. Mixed comparison of stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Archives of Internal Medicine 2006;166:1269-1275.
71. Collett D. Modelling Survival Data in Medical Research, 2nd edn. New York: Chapman and Hall/CRC, 2003.
72. Parmar M.K.B., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-2834.
73. Tengs T.O., Lin T.H. A meta-analysis of quality-of-life estimates for stroke. PharmacoEconomics 2003;21(3):191-200.
74. Cooper N.J., Sutton A.J., Mugford M., et al. Use of Bayesian Markov Chain Monte Carlo methods to model cost-of-illness data. Medical Decision Making 2003; 23:38-53.
75. Smaill F., Hofmeyr G. Antibiotic prophylaxis for cesarean section. Cochrane Review 2001(3).
76. Bibi M., Megdiche H., Ghanem H., et al., L'antibioprophylaxie dans les cesariennes a priori sans 'haut risque infectieux'. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris) 1994;23:451-455.
77. Deeks J.J., Altman D.G. Effect measures for meta-analysis of trials with binary outcomes. In: Egger M., Davey Smith G., Altman D.G., eds. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing Group, 2001;313-335.
78. Mugford M., Kingston J., Chalmers I. Reducing the incidence of infection after caesarean section: implications of prophylaxis with antibiotics for hospital resources. British Medical Journal 1989;299:1003-1006.
79. Ades A.E., Claxton K., Sculpher M., Evidence synthesis, parameter correlation and probablistic sensitivity analysis. Health Economics 2006;15:373-382.
80. Black W.C. The CE plane: a graphic representation of cost-effectiveness. Medical Decision Making 1990;10:212-214.
81. van Hout B.A., Malwenn J.A., Gordon G.S., et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 1994;3:309-319.
82. Stinnett A.A., Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 1998;18(Suppl.):S68-S80.
83. Spiegelhalter D.J., Myles J.P., Jones D.R., et al. Methods in health service research:an introduction to Bayesian methods in health technology assessment. British Medical Journal 1999;319:508-512.
84. StataCorporation, Stata Statistical Software: Release 10 . College Station, TX: StataCorp LP, 2007.
85. Coyle D., Lee K.M. Evidence-based economic evaluation: how the use of different data sources can impact results. In: Donaldson C., Mugford M., Vale L., eds. Evidence-Based Health Economics: From Effectiveness to Efficiency in Systematic Review. London: BMJ Publishing Group, 2002;55-66.
86. Cooper N.J., et al. Use of evidence in decision models: an appraisal of health technology assessments in the UK to date. Journal of Health Services Research and Policy 2005;10(4):245-250.
87. Daniels M.J., Hughesd- M.D. Meta-analysis for the evaluation of the potential surrogate markers. Statistics in Medicine 1997:16:1965-1982.
88. Philips Z., Ginnelly L., Sculpher M., et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment 2004;8(36).
89. CRD. Undertaking systematic reviews of research on effectiveness: CRD's guidance for carrying out or commissioning reviews. In: Centre for Reviews and Dissemination Report 4 . York: University of York, 2001.
90. Golder S., Glanville J., Ginnelly L. Populating decision-analytic models: The feasibility and efficiency of database searching for individual parameters. International Journal of Technology Assessment in Health Care 2005;21(3):305-311.
91. Hartley R.J., Keen E.M., Large J.A., et al. Online Searching: Principles and Practice. London: Bowker Saur, 1990.
92. Bates M.J. The design of browsing and berrypicking techniques for the online search interface. Online Review 1989;13:407-424.
93. Sculpher M.J. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008;26:799-806.
94. Bojke L., Claxton K., Sculpher M., et al. Characterising structural uncertainty in decision-analytic models: a review and application of methods. Value in Health 2009;15(5):739-749.
95. Jackson C.H., Thompson S.G., Sharples L.D. Accounting for uncertainty in health economic decision models by using model averaging. Journal of the Royal Statistical Society, Series A 2009;172(2):383-404.
96. Briggs A., Sculpher M., Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
97. Petrou S., Gray A. Economic evaluation using decision analytical modelling design, conduct, analysis, and reporting. British Medical Journal 2011;342:d1766.
98. Sutton A.J., Abrams K.R., Jones D.R., Sheldon T.A., Song F. Methods for Meta-Analysis in Medical Research. London: John Wiley & Sons, Ltd, 2000.
99. Deeks J., Glanville J., Sheldon T. Undertaking systematic reviews of research on effectiveness:CRD guidelines for those carrying out or commissioning reviews. Centre for Reviews and Dissemination Report Number 4 (2nd edn). York: York Publishing Services Ltd, 1996.
100. Higgins J.P.T., Green S., eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Chichester: Tne Cochrane Collaboration, John Wiley & Sons, Ltd, 2005.
101. Cooper N.J., Sutton A.J., Ades A., Paisley S., Jones D.R. Use of evidence in economic decision models: practical issues and methodological challenges. Health Economics 2007;16:1277-1286.
102. Sutton A.J., Higgins J.P.T. Recent developments in meta-analysis. Statistics in Medicine 2008;27:625-650.
103. Riley R.D., Lambert P.C., Abo-Zaid G. Meta-analysis of individual participant data:rationale, conduct, and reporting. British Medical Journal 2010;340:c221.
104. Hardy R.J., Thompson S.G. A likelihood approach to meta-analysis with random effects. Statistics in Medicine 1996;15:619-629.
105. Fleiss J.L. The statistical basis of meta-analysis. Statistical Methods in Medical Research 1993;2:121-145.
106. Lambert P., Sutton A.J., Burton P., Abrams K.R., Jones D.R. How vague is vague? Assessment in the use of vague prior distributions for variance components. Statistics in Medicine 2005;24:2401-2428.
107. Spiegelhalter D.J., Abrams K.R., Myles J.P. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester: John Wiley & Sons, Ltd, 2003.
108. Ades A.E., Lu G., Higgins J.P.T. The interpretation of random-effects meta-analysis in decision models. Medical Decision Making 2005;25:646-654.
109. Higgins J.P.T., Whitehead A. Borrowing strength from external trials in a meta-analysis. Statistics in Medicine 1996;15:2733-2749.
110. Smith T.C., Spiegelhalter D.J., Thomas A. Bayesian approaches to random-effects metaanalysis:a comparative study. Statistics in Medicine 1995;14:2685-2699.
111. Sweeting M.J., Sutton A.J., Lambert P.C. What to add to nothing? The use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23:1351-1375.
112. Rothstein H.R., Sutton A.J., Borenstein M.E. Publication Bias in Meta-Analysis -Prevention, Assesment and Adjustments. Chichester: John Wiley & Sons, Ltd, 2005.
113. Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H.R. Introduction to Meta-Analysis. Chichester: John Wiley & Sons, Ltd, 2009.
114. Thompson S.G., Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Statistics in Medicine 1999;18:2693-2708.
115. Berkey C.S., Hoaglin D.C., Mosteller F., Colditz G.A. A random-effects regression model for meta-analysis. Statistics in Medicine 1995;14:395-411.
116. Higgins J.P.T., Thompson S.G. Controlling the risk of spurious findings from metaregression. Statistics in Medicine 2004;23:1663-1682.
117. Lambert P., Sutton A.J., Abrams K.R., Jones D.R. A comparison of summary patient level covariates in meta-regression with individual patient data meta-analyses. Journal of Clinical Epidemiology 2002;55:86-94.
118. Riley R.D., Lambert P.C., Abo-Zaid G. Meta-analysis of individual participant data:rationale, conduct, and reporting. British Medical Journal 2010;340:c221.
119. Higgins J.P.T., Whitehead A., Turner R.M., et al . Meta-analysis of continuous outcome data from individual patients. Statistics in Medicine 2001;20:2219-2241.
120. Whitehead A., Omar R.Z., Higgins J.P.T., et al . Meta-analysis of ordinal outcomes using individual patient data. Statistics in Medicine 2001;20:2243-2260.
121. Turner R.M., Omar R.Z., Yang M., et al . A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2000;19:3417-3432.
122. Sutton A.J., Kendrick D., Coupland C.A.C. Meta-analysis of individual- and aggregatelevel data. Statistics in Medicine 2008;27:651-669.
123. Thompson S.G., Smith T.C., Sharp S.J. Investigating underlying risk as a source of heterogeneity in meta-analysis. Statistics in Medicine 1997;16:2741-2758.
124. Arends L.R., Hoes A.W., Lubsen J., et al . Baseline risk as predictor of treatment benefit; three clinical meta-re-analyses. Statistics in Medicine 2000;19:3497-3518.
125. McCullagh P., Nelder J.A. Generalised Linear Models. London: Chapman and Hall, 1989.
126. Yusuf S., Koon T., Woods K. An effective, safe, simple, and inexpensive intervention. Circulation 1993;87:2043-2046.
127. ISIS 4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
128. Sterne J.A.C., Bradburn M.J., Egger M. Meta-analysis in Stata. In: Egger M., Davey Smith G., Altman D.G., eds. Systematic Reviews in Health Care: Meta-Analysis in Context . London: BMJ Books, 2001;347-369.
129. Higgins J.P.T., Spiegelhalter D.J. Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction. International Journal of Epidemiology 2002;31:96-104.
130. Dempster A.P. The direct use of likelihood for significance testing. Statistics and Computing 1997;7:247-252.
131. Akaike H. A new look at the statistical model identification. IEEE Transations on Automatic Control 1974;19:716-723.
132. Spiegelhalter D.J., Best N.G., Carlin B.P., van der Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society, Series B 2002;64:583-616.
133. Spiegelhalter D.J., Thomas A., Best N., Lunn D. WinBUGS User Manual: Version 1.4 . Cambridge: MRC Biostatistics Unit, 2001.
134. Gelman A., Carlin J.G., Stern H.S., Rubin D.B. Bayesian Data Analysis. London: Chapman and Hall, 1995.
135. Stern H.S., Cressie N. Posterior predictive model checks for disease mapping models. Statistics in Medicine 2000;19:2377-2397.
136. Du Mouchel W. Predictive cross-validation of Bayesian meta-analyses. In: Bernardo J.M., Berger J.O., Dawid A.P., Smith A.F.M., eds. Bayesian Statistics 5 . Oxford: Oxford University Press, 1996;107-127.
137. Marshall E.C., Spiegelhalter D.J. Approximate cross-validatory predictive checks in disease mapping models. Statistics in Medicine 2003;22:1649-1660.
138. Egger M., Davey Smith G. Misleading meta-analysis. British Medical Journal 1995;310:752-754.
139. Colbourn T., Asseburg C., Bojke L., et al . Prenatal screening and treatment strategies to prevent Group B Streptococcal and other bacterial infections in early infancy: coste ffectiveness and expected value of information analysis. Health Technology Assessment 2007;11(29).
140. Mugford M. Using systematic reviews for economic evaluation. In: Egger M., Davey Smith G., Altman D., eds. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing, 2001;419-428.
141. Hunink M.G.M., Glasziou P., Siegel J., et al. Finding and summarizing the evidence. In:Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge:Cambridge University Press, 2001;214-244.
142. Cooper N.J., Sutton A.J., Ades A., Paisley S., Jones D.R., on behalf of the working group on the 'Use of evidence in economic decision models'. Use of evidence in economic decision models: Practical issues and methodological challenges. Health Economics 2007;16:1277-1286..
143. Sonnenberg F.A., Beck J.R. Markov models in medical decision making: a practical guide. Medical Decision Making 1993;13:322-338.
144. Cooper N.J., Abrams K.R., Sutton A.J., et al. Use of Bayesian methods for Markov modelling in cost-effectiveness analysis: an application to taxane use in advanced breast cancer. Journal of Royal Statistical Society, Series A 2003;166:389-405.
145. Cooper N.J., Sutton A.J., Abrams K.R. Decision analytical economic modelling within a Bayesian framework: Application to prophylactic antibiotics use for caesarean section. Statistical Methods in Medical Research 2002;11:491-512.
146. Cooper N.J., Sutton A.J., Abrams K.R., et al. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Economics 2004;13:203-226.
147. Spiegelhalter D.J., Best N.G. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Statistics in Medicine 2003;22:3687-3709.
148. Spiegelhalter D.J., Abrams K.R., Myles J.P. Bayesian Approaches to Clinical Trials and Health-Care Evaluation (Statistics in Practice). Chichester: John Wiley & Sons, Ltd, 2004.
149. Parmigiani G. Modeling in medical decision making: a Bayesian approach. In: Barnett V., ed. Statistics in Practice, Ist edn. Chichester: John Wiley & Sons, Ltd, 2002.
150. Smaill F., Hofmeyr G. Antibiotic prophylaxis for cesarean section. Cochrane Review 2001;(3).
151. Deeks J.J., Altman D.G. Effect measures for meta-analysis of trials with binary outcomes. In: Egger M., Davey Smith G., Altman D., eds. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing Group, 2001;313-335.
152. Prevost T.C., Abrams K.R., Jones D.R. Hierarchical models in generalised synthesis of evidence: an example based on studies of breast cancer. Statistics in Medicine 2000; 19:3359-3376.
153. Gilks W.R., Richardson S., Spiegelhalter D.J. Markov Chain Monte Carlo in Practice:Interdisciplinary Statistics. London: Chapman and Hall, 1996.
154. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17(5):479-500.
155. Brennan A., Akehurst R., Modelling in health economic evaluation: What is its place? What is its value? Pharmacoeconomics 2000;17:445-459.
156. Sutton A.J., Abrams K.R., Jones D.R., et al., Methods for Meta-Analysis in Medical Research. Chichester: John Wiley & Sons, Ltd, 2000.
157. Brown J., Welton N.J., Bankhead C., et al. A Bayesian approach to analysing the costeffectiveness of two primary care interventions aimed at improving attendance for breast screening. Health Economics 2006;15:435-445.
158. Cooper N.J., Sutton A.J., Abrams K.R., Turner D., Wailoo A. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Economics 2004; 13:203-226.
159. Gillies C L, Lambert P.C., Abrams K.R., et al. A cost-effectiveness analysis for different strategies for the screening and prevention of type 2 diabetes mellitus. British Medical Journal 2008;336:1180-1185.
160. Minelli C., Abrams K.R., Sutton A.J., Cooper N.J. Appropriate use of hormone replacement therapy (HRT): A clinical decision analysis. British Medical Journal 2004; 328:371-375.
161. Parmigiani G., Samsa G., Ancukiewicz M., et al. Assessing uncertainty in costeffectiveness analyses. Medical Decision Making 1997;17:390-401.
162. Sutton A.J., Cooper N., Abrams K.R., Lambert P.C., Jones D.R. Synthesising both benefit and harm: A Bayesian approach to evaluating clinical net benefit. Journal of Clinical Epidemiology 2005;58:26-40.
163. Vergel Y.B., Palmer S., Asseburg C., et al. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis Heart 2007;93:1238-1243.
164. Eddy D.M., Hasselblad V., Shachter R. Meta-analysis by the Confidence Profile Method. London: Academic Press, 1992.
165. Hasselblad V., McCrory D.C. Meta-analytic tools for medical decision making: a practical guide. Medical Decision Making 1995;15:81-96.
166. Ades A.E., Cliffe S. Markov Chain Monte Carlo estimation of a multi-parameter decision model: consistency of evidence and the accurate assessment of uncertainty. Medical Decision Making 2002;22:359-371.
167. Ades A.E., Sutton A.J. Multiparameter evidence synthesis in epidemiology and medical decision making: current approaches. Journal of the Royal Statistical Society, Series A 2006;169:5-35.
168. Spiegelhalter D.J., Abrams K.R., Myles J. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York: John Wiley & Sons, Ltd, 2004.
169. Dominici F., Parmigiani G., Reckhow K.H., Wolpert R.L. Combining information from related regressions. Journal of Agricultural, Biological, and Environmental Statistics 1997;2:313-332.
170. Dominici F., Parmigiani G., Wolpert R.L., Hasselblad V. Meta-analysis of migraine headache treatments: combining information from heterogenous designs. Journal of the American Statistical Association 1999;94:16-28.
171. Dominici F. Combining contingency tables with missing dimensions. Biometrics 2000; 56:546-553.
172. Goubar A., Ades A.E., De Angelis D., et al. Bayesian multi-parameter synthesis of HIV surviellance data in England and Wales, 2001. Technical Report. London: Health Protection Agency Centre for Infections, 2006.
173. Sweeting M.J., De Angelis D., Hickman D., Ades A.E. Estimating HCV prevalence in England and Wales by synthesising evidence from multiple data sources: assessing data conflict and model fit. Biostatistics 2008;9:715-734.
174. Welton N.J., Ades A.E. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence. Applied Statistics 2005;54:385-404.
175. Spiegelhalter D.J., Best N.G., Carlin B.P., van der Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society, Series B 2002;64:583-616.
176. Presanis A., De Angelis D., Spiegelhalter D., et al. Conflicting evidence in a Bayesian synthesis of surveillance data to estimate HIV prevalence. Journal of the Royal Statistical Society, Series A 2008;171:915-937.
177. Turner R.M., Spiegelhalter D.J., Smith G.C.S., Thompson S.G. Bias modelling in evidence synthesis. Journal of the Royal Statistical Society, Series A 2009;172:21-47.
178. Ades A.E., Welton N., Caldwell D., et al. Multiparameter evidence synthesis in epidemiology and medical decision-making. Journal of Health Services & Research Policy 2008; 13(Suppl. 3):12-22.
179. Gaver D., Draper D., Goel P., et al. Combining Information: Statistical Issues and Opportunities for Research. Washington, DC: National Academy Press, 1992.
180. Raftery A.E., Givens G.H., Zeh J.E. Inference from a deterministic population dynamics model for Bowhead whales (with discussion). Journal of the American Statistical Association 1995;90:402-430.
181. Brand K.P., Small M.J. Updating uncertainty in an integrated risk assessment: conceptual framework and methods. Risk Analysis 1995;15:719-731.
182. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Chichester: The Cochrane Collaboration, John Wiley & Sons, Ltd, 2008.
183. Bucher H.C., Guyatt G.H., Griffith L.E., Walter S.D. The results of direct and indirect treatment comparisons in meta-analysis of Randomized Controlled Trials. Journal of Clinical Epidemiology 1997;50:683-691.
184. Boland A., Dundar Y., Bagust A., et al. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. Health Technology Assessment 2003;7:1-136.
185. Eddy D.M., Hasselblad V., Shachter R. Meta-analysis by the Confidence Profile Method. London: Academic Press, 1992.
186. Lu G., Ades A. Assessing evidence consistency in mixed treatment comparisons. Journal of the American Statistical Association 2006;101:447-459.
187. Hasselblad V. Meta-analysis of multi-treatment studies. Medical Decision Making 1998;18:37-43.
188. Higgins J.P.T., Whitehead A. Borrowing strength from external trials in a meta-analysis. Statistics in Medicine 1996;15:2733-2749.
189. Cipriani A., Furukawa T.A., Salanti G., et al. Comparative efficacy and acceptability of 12 new generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-758.
190. Song F., Altman D., Glenny A-M, Deeks J. Validity of indirect comparison for estimating efficacy of competing interventions: evidence from published meta-analyses. British Medical Journal 2003;326:472-476.
191. Chou R., Fu R., Hoyt Huffman L., Korthuis P.T. Initial highly-active antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006;368:1503-1515.
192. Caldwell D.M., Ades A.E., Higgins J.P.T. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal 2005;331:897-900.
193. Salanti G., Higgins J.P.T., Ades A.E., Ioannidis J.P.A. Evaluation of networks of randomised trials. Statistical Methods in Medical Research 2008;17:279-301.
194. Sutton A.J., Ades A.E., Cooper N., Abrams K.R. Use of mixed and indirect comparisons in technology assessment. Pharmacoeconomics 2008;26:753-767.
195. Song F., Xiong T., Parekh-Bhurke S., et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. British Medical Journal 2011;343: d4909.
196. Caldwell D.M., Gibb D.M., Ades A.E. Validity of indirect comparisons in meta-analysis.[Letter.] Lancet 2007;369: 270.
197. Ades A.E., Dias S., Welton N.J. Song et al have not demonstrated inconsistency between direct and indirect comparisons (online letter). 2011. British Medical Journal 2011.
198. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee, Version 4.3 . Canberra: Australian Government, Department of Health and Aging, 2008.
199. Jansen J., Fleurence R., Devine B., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value in Health 2011;14:417-428.
200. Hoaglin D.C., Hawkins N., Jansen J.P., et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. Value in Health 2011;14:429-437.
201. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002;21:2313-2324.
202. O'Hagan A. HSSS model criticism (with discussion). In: Green P.J., Hjort N.L., Richardson S.T., eds. Highly Structured Stochastic Systems. Oxford: Oxford University Press, 2002; 423-453.
203. Dias S., Welton N.J., Caldwell D.M., Ades A.E. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29:932-944.
204. Lu G., Ades A.E. Modelling between-trial variance structure in mixed treatment comparisons. Biostatistics 2009;10:792-805.
205. Lu G., Welton N.J., Higgins J.P.T., White I.R., Ades A.E. Linear inference for mixed treatment comparison meta-analysis: a two-stage approach. Research Synthesis Methods 2011;2:43-60.
206. Ades A.E. A chain of evidence with mixed comparisons: models for multiparameter evidence synthesis and consistency of evidence. Statistics in Medicine 2003;22:2995-3016.
207. Lu G., Ades A.E., Sutton A.J., et al. Meta-analysis of mixed treatment comparisons at multiple follow-up times. Statistics in Medicine 2007;26:3681-3699.
208. Welton N.J., Cooper N.J., Ades A.E., Lu G., Sutton A.J. Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B. Statistics in Medicine 2008;27:5620-5639.
209. Welton N.J., Willis S.R., Ades A.E. Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies. Research Synthesis Methods 2010;1:239-257.
210. Briggs A.H., Ades A.E., Price M.J. Probabilistic sensitivity analysis for decision trees with multiple branches: Use of the Dirichlet distribution in a Bayesian framework. Medical Decision Making 2003;23:341-350.
211. Price M., Welton N., Ades A.E. Parameterisation of treatment effects for meta-analysis in multi-state Markov models. Statistics in Medicine 2011;30:140-151.
212. Price M.J., Welton N.J., Briggs A.H., Ades A.E. Model averaging in the presence of structural uncertainty about treatment effects: inflence on treatment decision and expected value of information. Value in Health 2011;14:205-218.
213. Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan F., ed. Valuing Health Care. Cambridge: Cambridge University Press, 1996; 185-205.
214. Sonnenberg F.A., Beck J.R. Markov models in medical decision making: a practical guide. Medical Decision Making 1993;13:322-338.
215. Briggs A., Sculpher M., Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
216. Hunink M., Glasziou P., Siegel J., et al. Decision Making in Health and Medicine:Integrating Evidence and Values. Cambridge: Cambridge University Press, 2001.
217. Briggs A.H., Ades A.E., Price M.J. Probabilistic sensitivity analysis for decision trees with multiple branches: Use of the Dirichlet distribution in a Bayesian framework. Medical Decision Making 2003;23:341-350.
218. Gelman A., Carlin J.G., Stern H.S., Rubin D.B. Bayesian Data Analysis. London: Chapman and Hall, 1995.
219. Welton N.J., Ades A.E. Estimation of Markov chain transition probabilities and rates from fully and partially observed data: Uncertainty propagation, evidence synthesis and model calibration. Medical Decision Making 2005;25:633-645.
220. Grimmett G.D.R., Stirzaker D.R. Probability and Random Processes. Oxford: Oxford University Press, 1992.
221. Lunn D. WinBUGS Differential Interface (WBDiff). http://www.winbugsdevelopment. org.uk/. 2004.
222. Price M., Welton N., Ades A.E. Parameterisation of treatment effects for meta-analysis in multi-state Markov models. Statistics in Medicine 2011;30:140-151.
223. Price M.J., Welton N.J., Ades A.E. Parameterising the effect of cotrimoxazole prophylaxis in a multi-state Markov model of HIV disease progression in African children. International Society for Clinical Biostatistics, 28th Annual Conference, Alexandroupolis, Greece, 2007; Abstract.
224. Black N. Why we need observational studies to evaluate the effectiveness of health care. British Medical Journal 1996;312:1215-1218.
225. Turner R.M., Spiegelhalter D.J., Smith G.C.S., Thompson S.G. Bias modelling in evidence synthesis. Journal of the Royal Statistical Society, Series A 2009;172:21-48.
226. Welton N.J., Ades A.E., Carlin J., et al. Models for potentially biased evidence in meta-analysis using empirically based priors. Journal of the Royal Statistical Society, Series A 2009;172:119-136.
227. Torgerson D.J., Bell-Syer S.E. Hormone replacement therapy and prevention of vertebral fractures: A meta-analysis of randomised trials. BMC Musculoskeletal Disorders 2001;2:7.
228. Torgerson D.J., Bell-Syer S.E. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. Journal of the American Medical Association 2001;285(22):2891-2897.
229. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350(9084):1047-1059.
230. Ibrahim J.G., Chen M.H. Power prior distributions for regression models. Statistical Science 2000;15:46-60.
231. Sacks H.S., Chalmers T.C., Smith H. Randomized versus historical controls for clinical trials. American Journal of Medicine 1982;72:233-240.
232. Ioannidis J.P.A., Haidich A.-B., Pappa M., et al. Comparison of evidence of treatment effects in randomised and nonrandomised studies. Journal of the American Medical Association 2001;286:821-830.
233. MacLehose R.R., Reeves B.C., Harvey I.M., et al. A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. Health Technology Assessment 2000;4(34):1-154.
234. Deeks J.J., Dinnes J., D'Amico R., et al. Evaluating non-randomised intervention studies. Health Technology Assessment 2003;7(27).
235. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association 2002;288:321-333.
236. Prevost T.C., Abrams K.R., Jones D.R. Hierarchical models in generalised synthesis of evidence: an example based on studies of breast cancer screening. Statistics in Medicine 2000;19:3359-3376.
237. Hornbuckle J., Vail A., Abrams K.R., Thornton J.G. Bayesian interpretation of trials:the example of intrapartum electronic fetal heart rate monitoring. British Journal of Obstetrics and Gynaecology 2000;107:3-10.
238. Deeks J.J. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2002;21(11):1575-1600.
239. Sutton A.J., Abrams K.R. Bayesian methods in meta-analysis and evidence synthesis. Statistical Methods in Medical Research 2001;10:277-303.
240. Peters J.L., Rushton L., Sutton A.J., et al. Bayesian methods for the cross-design synthesis of epidemiological and toxicological evidence. Journal of the Royal Statistical Society, Series C 2005;54:159-172.
241. Droitcour J., Silberman G., Chelimsky E. Cross-design synthesis: A new form of meta-analysis for combining results from randomized clinical trials and medicalpractice databases. International Journal of Technology Assessment in Health Care 1993;9:440-449.
242. Eddy D.M. The confidence profile method: A Bayesian method for assessing health technologies. Operations Research 1989;37:210-228.
243. Eddy D.M., Hasselblad V., Shachter R. Meta-Analysis by the Confidence Profile Method. San Diego: Academic Press, 1992.
244. Li Z.H., Begg C.B. Random effects models for combining results from controlled and uncontrolled studies in a metaanalysis. Journal of the American Statistical Association 1994;89:1523-1527.
245. Larose D.T., Dey D.K. Grouped random effects models for Bayesian meta-analysis. Statistics in Medicine 1997;16:1817-1829.
246. DuMouchel W.H., Harris J.E. Bayes methods for combining the results of cancer studies in humans and other species (with comment). Journal of the American Statistical Association 1983;78:293-308.
247. Jones D.R., Peters J., Rushton L., et al. Interspecies extrapolation in environmental exposure standard setting: a Bayesian synthesis approach. Regulatory Toxicology and Pharmacology 2009;53:217-225.
248. Anonymous. Listening to your baby's heartbeat during labour. Midwives Information and Resource Service (MIDIRS) and the NHS Centre for Reviews and Dissemination. Bristol: MIDIRS, 1995.
249. Neilson J. EFM plus scalp sampling vs intermittent auscultation in labour. In: Enkin M.W., Keirse M.J.N.C., Renfrew M.J., Neilson J.P., eds. Cochrane database of systematic reviews: pregnancy and childbirth module. Cochrane updates on disk: Issue 1. Oxford: Update Software, 1994.
250. Thacker S.B., Stroup D.F., Peterson H.B. Continuous electronic fetal heart rate monitoring during labour. In: Neilson J.P., Crowther C.A., Hodnett E.D., Hofmeyer G.J., Keirse M.J.N.C., eds. Cochrane database of systematic reviews: pregnancy and childbirth module. Cochrane updates on disk: Issue 2. Oxford: Update Software, 1997.
251. Ades A.E., Cliffe S. Markov Chain Monte Carlo estimation of a multi-parameter decision model: consistency of evidence and the accurate assessment of uncertainty. Medical Decision Making 2002;22:359-371.
252. Ades A., Lu G., Claxton K. Expected value of sample information calculations in medical decision modeling. Medical Decision Making 2004;24:207-227.
253. Pratt J.W., Raiffa H., Schlaiffer R. Statistical Decision Theory. Cambridge, MA:Massachusetts Institute of Technology, 2001.
254. Raiffa H., Schlaiffer R. Applied Statistical Decision Theory. New York: Wiley Interscience, 1967.
255. Claxton K., Ades A.E. Efficient research design: an application of value of information analysis to an economic model of zanamivir. In: Proceedings of the 24th Meeting of the Society for Medical Decision Making. Baltimore: 2002.
256. Brennan A., Kharroubi S.A. Expected Value of Sample Information for Weibull survival data. Health Economics 2007;16:1205-1225.
257. Claxton K., Neumann P.J., Araki S., Weinstein M.C. Bayesian value-of-information analysis: An application to a policy model of Alzheimer's disease. International Journal of Technology Assessment in Health Care 2001;17:38-55.
258. Thompson K.M., Evans J.S. The value of improved national exposure information for perchloroethylene (Perc): a case study for dry cleaners. Risk Analysis 1997;17:253-271.
259. Claxton K.P., Sculpher M.J. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006;24:1055-1068.
260. Colbourn T., Asseburg C., Bojke L., et al. Prenatal screening and treatment strategies to prevent Group B Streptococcal and other bacterial infections in early infancy: costeffectiveness and expected value of information analysis. Health Technology Assessment 2007;11:1-226.
261. Colbourn T.E., Asseburg C., Bojke L., et al. Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses. British Medical Journal 2007;335:655-661.
262. Yokota F., Thompson K.M. Value of information analysis in environmental health risk management decisions: past, present and future. Risk Analysis 2004;24:635-650.
263. Yokota F., Thompson K.M. Value of information literature analysis: A review of applications in health risk management. Medical Decision Making 2004;24:287-298.
264. Brennan A., Kharroubi S.A. Efficient computation of partial expected value of sample information using Bayesian approximation. Health Economics 2007;26:122-148.
265. Eckermann S., Willan A.R. Expected value of information and decision making in HTA. Health Economics 2007;16:195-209.
266. Felli J.C., Hazen G.B. Sensitivity analysis and the expected value of perfect information. Medical Decision Making 1998;18:95-109.
267. Felli J.C., Hazen G. A Bayesian approach to sensitivity analysis. Health Economics 1999;8:263-268.
268. Tappenden P., Chilcott J.B., Eggington S., et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis. Health Technology Assessment 2004;8(27).
269. Welton N.J., Ades A.E., Caldwell D.M., Peters T.J. Research prioritisation based on Expected Value of Partial Perfect Information: A case study on interventions to increase uptake of breast cancer screening. Journal of the Royal Statistical Society, Series A 2008;171:807-841.